Lindbrook Capital, LLC Atea Pharmaceuticals, Inc. Transaction History

Lindbrook Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Jul 28, 2023	BUY	$3.21 - $5.06 $215 - $339	67 Added 21.54%	378 $1,000
Q1 2023 Apr 26, 2023	BUY	$3.0 - $4.97 $12 - $19	4 Added 1.3%	311 $1,000
Q4 2022 Jan 24, 2023	BUY	$4.35 - $6.17 $78 - $111	18 Added 6.23%	307 $0
Q3 2022 Nov 10, 2022	SELL	$5.49 - $8.79 $131 - $210	-24 Reduced 7.67%	289 $2,000
Q2 2022 Aug 01, 2022	BUY	$5.33 - $8.18 $1,668 - $2,560	313 New	313 $2,000
Q1 2022 Apr 21, 2022	SELL	$5.5 - $9.19 $275 - $459	-50 Closed	0 $0
Q4 2021 Jan 18, 2022	BUY	$7.67 - $44.59 $383 - $2,229	50 New	50 $0

111

50.9M

7.6K

38.7K

Ticker AVIR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,258,600
Market Cap $258M
Description
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...

Get notified when there are updates to the investment portfolio of Lindbrook Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Lindbrook Capital, LLC with notifications on news.